Samsung Biologics said Wednesday that it has launched S-Cellerate, a pharmaceutical consignment development organization (CDO) platform that shortens the period for developing drugs, at the 2021 BioProcess International Conference.
According to the company, S-Cellerate significantly shortens the time required for all processes ranging from cell line development to investigational new drug (IND) application and from process characterization (PC) to biologics license application (BLA).
"S-Cellerate has integrated Samsung Biologics' accumulated know-how, expertise, and innovative technology across all areas of consignment development organization services," the company said. "The platform standardizes the services required for biopharmaceutical development and supports them more quickly, and consists of two services."
One of the two services is S-Cellerate to IND platform service, which supports from initial cell line development to the production process and analysis method development, non-clinical and clinical material production, and IND. The other is S-Cellerate to BLA platform service, a platform service from late-stage through PC confirmation and process performance qualification (PPQ) to application for (BLA for commercial sales, the company explained.
"Through the CDO service built on the foundation of Samsung Biologics' rich experience, data, and expertise, customers can dramatically shorten the development period for biopharmaceuticals and reduce the total cost of ownership (TCO) invested in R&D," Samsung Biologics CEO John Rim also said. “In keeping with the changing market, Samsung Biologics will continue to innovate its services to realize the highest customer satisfaction and allow innovative biologics to enter the market faster.”
According to the company, the new platform is the latest service provided by the company as it strives to become a leader in the CDO market.
Samsung Biologics' CDO service has won a record-high of 81 contracts in three years since entering the market in 2018.
"One of our core competitiveness is to help biopharmaceutical development companies save time and money through the one-stop service thanks to the discovery of candidate substances to the production of clinical samples and mass production for commercial purposes," the company said. “Since the launch of our cell line S-CHOice, which significantly improved cell proliferation and viability in August last year, the number of projects that have adopted the new cell line has increased significantly.”
The company plans to provide prompt service and enhance its competitiveness to win more orders, it added.